rank,company,total_score,fit_score,urgency_score,access_score,trial_count,best_fit_trial_title,best_fit_trial_status,best_fit_trial_phases,best_fit_trial_last_update,best_urgency_trial_title,best_urgency_trial_status,best_urgency_trial_phases,best_urgency_trial_last_update,recent_job_hits,fit_reason,urgency_reason,urgency_source,access_reason,bonus_recent_trial,bonus_multi_trial,trigger_summary,evidence_links,target_roles,job_hit_keywords,job_hit_titles
1,Pfizer,9.10,3.0,3.0,2.0,9,A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30),RECRUITING,"[""PHASE1""]",2026-02-05,A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30),RECRUITING,"[""PHASE1""]",2026-02-05,0,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE1'],trial,company on watchlist / ATS known,0.5,0.6,trial_candidate: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | trial_candidate: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | trial_candidate: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments,https://clinicaltrials.gov/study/NCT06215118 ; https://clinicaltrials.gov/study/NCT06152575 ; https://clinicaltrials.gov/study/NCT05020236 ; https://clinicaltrials.gov/study/NCT06057402 ; https://clinicaltrials.gov/study/NCT06974786 ; https://clinicaltrials.gov/study/NCT05090566 ; https://clinicaltrials.gov/study/NCT04649359 ; https://clinicaltrials.gov/study/NCT06421675,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
2,AstraZeneca,9.10,3.0,3.0,2.0,7,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-10,"A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-10,0,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,company on watchlist / ATS known,0.5,0.6,"trial_candidate: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. | trial_candidate: A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | trial_candidate: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",https://clinicaltrials.gov/study/NCT06542250 ; https://clinicaltrials.gov/study/NCT06564038 ; https://clinicaltrials.gov/study/NCT05877599 ; https://clinicaltrials.gov/study/NCT06218914 ; https://clinicaltrials.gov/study/NCT06005493 ; https://clinicaltrials.gov/study/NCT07215585 ; https://clinicaltrials.gov/study/NCT07201558,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
3,"Janssen Research & Development, LLC",8.10,3.0,3.0,1.0,5,Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-16,Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-16,0,trial title contains known T-cell engager molecule,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.6,trial_candidate: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | trial_candidate: Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT05201781 ; https://clinicaltrials.gov/study/NCT03399799 ; https://clinicaltrials.gov/study/NCT04634552 ; https://clinicaltrials.gov/study/NCT07029776 ; https://clinicaltrials.gov/study/NCT06348108,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
4,Regeneron Pharmaceuticals,8.10,3.0,3.0,1.0,14,A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma,ACTIVE_NOT_RECRUITING,"[""PHASE3""]",2026-02-06,"A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-02-06,0,trial title contains known T-cell engager molecule,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.6,"trial_candidate: A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | trial_candidate: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma | trial_candidate: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",https://clinicaltrials.gov/study/NCT05828511 ; https://clinicaltrials.gov/study/NCT06097364 ; https://clinicaltrials.gov/study/NCT06149286 ; https://clinicaltrials.gov/study/NCT06091865 ; https://clinicaltrials.gov/study/NCT06469281 ; https://clinicaltrials.gov/study/NCT05730036 ; https://clinicaltrials.gov/study/NCT06932562 ; https://clinicaltrials.gov/study/NCT06787612,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
5,"Genentech, Inc.",8.10,3.0,3.0,1.0,5,Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma,RECRUITING,"[""PHASE2""]",2026-02-02,Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma,RECRUITING,"[""PHASE2""]",2026-02-02,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.6,"trial_collaborator: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | trial_collaborator: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | trial_collaborator: Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma",https://clinicaltrials.gov/study/NCT05633615 ; https://clinicaltrials.gov/study/NCT06357676 ; https://clinicaltrials.gov/study/NCT05464329 ; https://clinicaltrials.gov/study/NCT06252675 ; https://clinicaltrials.gov/study/NCT06249191,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
6,Amgen,8.10,3.0,3.0,1.0,6,"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",RECRUITING,"[""PHASE2""]",2025-11-10,Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab,RECRUITING,"[""PHASE2""]",2026-02-04,0,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.6,"trial_collaborator: Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab | trial_candidate: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | trial_candidate: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer",https://clinicaltrials.gov/study/NCT07061080 ; https://clinicaltrials.gov/study/NCT06555796 ; https://clinicaltrials.gov/study/NCT04221542 ; https://clinicaltrials.gov/study/NCT06613100 ; https://clinicaltrials.gov/study/NCT03263572 ; https://clinicaltrials.gov/study/NCT06816394,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
7,"CARsgen Therapeutics Co., Ltd.",7.95,3.0,3.0,1.0,4,"A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus",RECRUITING,"[""EARLY_PHASE1""]",2026-01-14,"Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE",RECRUITING,"[""PHASE1""]",2025-11-24,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.44999999999999996,"trial_collaborator: A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus | trial_collaborator: Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE | trial_collaborator: A Study of CT0596 in Plasma Cell Leukemia",https://clinicaltrials.gov/study/NCT07339332 ; https://clinicaltrials.gov/study/NCT07031713 ; https://clinicaltrials.gov/study/NCT06988059 ; https://clinicaltrials.gov/study/NCT05911217,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
8,Genmab,7.95,3.0,3.0,1.0,4,Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma,ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2026-02-04,Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma,ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2026-02-04,0,trial title contains known T-cell engager molecule,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.44999999999999996,trial_candidate: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | trial_candidate: GEN1047 for Solid Tumors - First in Human (FIH) Trial | trial_candidate: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome,https://clinicaltrials.gov/study/NCT05660967 ; https://clinicaltrials.gov/study/NCT05180474 ; https://clinicaltrials.gov/study/NCT04623541 ; https://clinicaltrials.gov/study/NCT06536049,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
9,AbbVie,7.95,3.0,3.0,1.0,4,"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",RECRUITING,"[""PHASE1""]",2026-02-10,"Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia",RECRUITING,"[""PHASE1""]",2026-02-10,0,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.44999999999999996,"trial_collaborator: Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia | trial_candidate: A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma | trial_collaborator: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma",https://clinicaltrials.gov/study/NCT04872790 ; https://clinicaltrials.gov/study/NCT03933735 ; https://clinicaltrials.gov/study/NCT05660967 ; https://clinicaltrials.gov/study/NCT04623541 ; https://clinicaltrials.gov/study/NCT07097363 ; https://clinicaltrials.gov/study/NCT06536049,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
10,Takeda,7.80,3.0,3.0,1.0,3,"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",RECRUITING,"[""PHASE2""]",2025-11-10,"Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia",RECRUITING,"[""PHASE2""]",2025-11-10,0,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.3,"trial_candidate: A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma | trial_collaborator: Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia | trial_candidate: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)",https://clinicaltrials.gov/study/NCT06980480 ; https://clinicaltrials.gov/study/NCT03263572 ; https://clinicaltrials.gov/study/NCT05020015,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
11,Cullinan Therapeutics Inc.,7.80,3.0,3.0,1.0,3,"A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease",RECRUITING,"[""PHASE1""]",2025-11-19,"A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease",RECRUITING,"[""PHASE1""]",2025-11-19,0,trial title indicates T-cell engager / T-cell engaging / T-cell redirecting,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,"trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | trial_candidate: A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis | trial_candidate: A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)",https://clinicaltrials.gov/study/NCT07041099 ; https://clinicaltrials.gov/study/NCT06994143 ; https://clinicaltrials.gov/study/NCT05879744,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
12,"TScan Therapeutics, Inc.",7.80,3.0,3.0,1.0,3,A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2025-11-17,A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2025-11-17,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.3,"trial_candidate: A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | trial_candidate: A Long Term Follow-up Study of TScan TCR-T Products | trial_candidate: A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation",https://clinicaltrials.gov/study/NCT05973487 ; https://clinicaltrials.gov/study/NCT06976736 ; https://clinicaltrials.gov/study/NCT05473910,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
13,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",7.65,3.0,3.0,1.0,2,Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE2""]",2026-02-10,Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE2""]",2026-02-10,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.15,"trial_candidate: Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | trial_candidate: A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma",https://clinicaltrials.gov/study/NCT06297226 ; https://clinicaltrials.gov/study/NCT06121843,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
14,"Kite, A Gilead Company",7.65,3.0,3.0,1.0,2,Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL,RECRUITING,"[""PHASE2""]",2026-01-08,Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL,RECRUITING,"[""PHASE2""]",2026-01-08,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.15,trial_candidate: A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | trial_collaborator: Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL,https://clinicaltrials.gov/study/NCT06413498 ; https://clinicaltrials.gov/study/NCT06104592,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
15,"Hebei Senlang Biotechnology Inc., Ltd.",7.65,3.0,3.0,1.0,2,Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.,NOT_YET_RECRUITING,"[""PHASE2""]",2025-11-24,Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.,NOT_YET_RECRUITING,"[""PHASE2""]",2025-11-24,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status NOT_YET_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.15,trial_candidate: Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL. | trial_candidate: Assessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL,https://clinicaltrials.gov/study/NCT07244380 ; https://clinicaltrials.gov/study/NCT07244406,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
16,Eli Lilly and Company,7.65,3.0,3.0,1.0,2,Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma,RECRUITING,"[""PHASE2""]",2025-10-22,A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ),NOT_YET_RECRUITING,"[""PHASE1""]",2026-02-10,0,trial title contains known T-cell engager molecule,trial status NOT_YET_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.15,trial_candidate: A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) | trial_collaborator: Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome | trial_collaborator: Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT07101328 ; https://clinicaltrials.gov/study/NCT04623541 ; https://clinicaltrials.gov/study/NCT06252675,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
17,"Corregene Biotechnology Co., Ltd",7.65,3.0,3.0,1.0,2,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-30,KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors,ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2026-01-30,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.15,trial_candidate: KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | trial_candidate: CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers,https://clinicaltrials.gov/study/NCT06767046 ; https://clinicaltrials.gov/study/NCT06358053,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
18,Carina Biotech Limited,7.50,3.0,3.0,1.0,1,"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-13,"A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",RECRUITING,"[""PHASE1"", ""PHASE2""]",2026-01-13,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.5,0.0,"trial_candidate: A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer",https://clinicaltrials.gov/study/NCT05759728,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
19,"Chongqing Precision Biotech Co., Ltd",7.50,3.0,3.0,1.0,1,A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2025-11-26,A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2025-11-26,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_collaborator: A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT07250386,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
20,"Ucello Therapeutics Co., Limited",7.50,3.0,3.0,1.0,1,"Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma",RECRUITING,"[""PHASE1""]",2025-11-25,"Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma",RECRUITING,"[""PHASE1""]",2025-11-25,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,"trial_collaborator: Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma",https://clinicaltrials.gov/study/NCT07139509,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
21,Johnson & Johnson,7.50,3.0,3.0,1.0,1,Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,RECRUITING,"[""PHASE2""]",2026-01-20,Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,RECRUITING,"[""PHASE2""]",2026-01-20,0,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.5,0.0,trial_collaborator: Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma,https://clinicaltrials.gov/study/NCT05972135,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
22,Imugene Limited,7.50,3.0,3.0,1.0,1,A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS),ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2025-12-18,A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS),ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2025-12-18,0,trial title contains known T-cell engager molecule,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS),https://clinicaltrials.gov/study/NCT06063317,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
23,"Shanghai Ruiliyuan Biotechnology Co., Ltd.",7.50,3.0,3.0,1.0,1,HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,RECRUITING,"[""PHASE1""]",2025-12-02,HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,RECRUITING,"[""PHASE1""]",2025-12-02,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.5,0.0,trial_candidate: HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors,https://clinicaltrials.gov/study/NCT06515314,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
24,Lion TCR Pte. Ltd.,7.30,3.0,3.0,1.0,3,Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma,RECRUITING,"[""PHASE1""]",2025-05-08,Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma,RECRUITING,"[""PHASE1""]",2025-05-08,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.3,trial_candidate: Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma | trial_candidate: Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC | trial_candidate: Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV),https://clinicaltrials.gov/study/NCT06961617 ; https://clinicaltrials.gov/study/NCT05195294 ; https://clinicaltrials.gov/study/NCT04745403,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
25,"Iovance Biotherapeutics, Inc.",7.30,3.0,3.0,1.0,3,E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers,RECRUITING,"[""PHASE2""]",2025-03-30,E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-08-19,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.3,"trial_collaborator: E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | trial_collaborator: E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | trial_collaborator: KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer",https://clinicaltrials.gov/study/NCT05639972 ; https://clinicaltrials.gov/study/NCT05686226 ; https://clinicaltrials.gov/study/NCT05483491,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
26,SCG Cell Therapy Pte. Ltd.,7.30,3.0,3.0,1.0,3,A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related,RECRUITING,"[""PHASE1""]",2024-09-27,A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-02-18,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.3,trial_candidate: A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma | trial_candidate: A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | trial_candidate: Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma,https://clinicaltrials.gov/study/NCT05417932 ; https://clinicaltrials.gov/study/NCT06617000 ; https://clinicaltrials.gov/study/NCT06505551,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
27,Yake Biotechnology Ltd.,7.15,3.0,3.0,1.0,2,CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-08-13,CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases,RECRUITING,"[""PHASE1"", ""PHASE2""]",2025-08-13,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.15,"trial_collaborator: CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases | trial_collaborator: Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial.",https://clinicaltrials.gov/study/NCT05827835 ; https://clinicaltrials.gov/study/NCT06836505,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
28,Carbiogene Therapeutics Co. Ltd.,7.15,3.0,3.0,1.0,2,Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma,RECRUITING,"[""PHASE1""]",2024-11-06,Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma,RECRUITING,"[""PHASE1""]",2024-11-06,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.15,trial_collaborator: Clinical Trial of Autologous GPC3 CAR-T Cells (CBG166) Therapy for Advanced Hepatocellular Carcinoma | trial_candidate: Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5),https://clinicaltrials.gov/study/NCT06461624 ; https://clinicaltrials.gov/study/NCT04803929,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
29,"Guangzhou FineImmune Biotechnology Co., LTD.",7.15,3.0,3.0,1.0,2,"An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",RECRUITING,"[""PHASE1""]",2025-09-03,"An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors",RECRUITING,"[""PHASE1""]",2025-09-03,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.15,"trial_candidate: An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors | trial_candidate: Individualized Tumor Specific TCR- T Cells in the Treatment of Advanced Solid Tumors",https://clinicaltrials.gov/study/NCT06942143 ; https://clinicaltrials.gov/study/NCT03891706,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
30,Takara Bio Inc.,7.00,3.0,3.0,1.0,1,"Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL",RECRUITING,"[""PHASE1""]",2025-07-02,"Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL",RECRUITING,"[""PHASE1""]",2025-07-02,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,"trial_collaborator: Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL",https://clinicaltrials.gov/study/NCT05963217,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
31,Beijing Yongtai Ruike Biotechnology Company Ltd,7.00,3.0,3.0,1.0,1,CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL,RECRUITING,"[""PHASE2""]",2025-01-13,CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL,RECRUITING,"[""PHASE2""]",2025-01-13,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.0,0.0,trial_candidate: CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL,https://clinicaltrials.gov/study/NCT06179524,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
32,Bristol-Myers Squibb,7.00,3.0,3.0,1.0,1,"Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2025-11-03,"Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",ACTIVE_NOT_RECRUITING,"[""PHASE2""]",2025-11-03,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.0,0.0,"trial_collaborator: A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | trial_collaborator: Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",https://clinicaltrials.gov/study/NCT06215118 ; https://clinicaltrials.gov/study/NCT04205409,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
33,UTC Therapeutics Inc.,7.00,3.0,3.0,1.0,1,Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies,RECRUITING,"[""PHASE1""]",2022-09-06,Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies,RECRUITING,"[""PHASE1""]",2022-09-06,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,trial_collaborator: Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies,https://clinicaltrials.gov/study/NCT05528887,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
34,Bio4T2 LLC,7.00,3.0,3.0,1.0,1,Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors,RECRUITING,"[""PHASE1""]",2023-10-10,Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors,RECRUITING,"[""PHASE1""]",2023-10-10,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,trial_collaborator: Repeat Intravenous Infusions of B4T2-001 CAR-T Without Lymphodepleting Chemotherapy for Solid Tumors,https://clinicaltrials.gov/study/NCT06072989,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
35,Kyverna Therapeutics,7.00,3.0,3.0,1.0,1,Anti-CD 19 CAR-T Cell Therapy in Patients with ANCA Vasculitis,NOT_YET_RECRUITING,"[""PHASE1"", ""PHASE2""]",2024-09-19,Anti-CD 19 CAR-T Cell Therapy in Patients with ANCA Vasculitis,NOT_YET_RECRUITING,"[""PHASE1"", ""PHASE2""]",2024-09-19,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,"trial status NOT_YET_RECRUITING and phase in ['PHASE1', 'PHASE2']",trial,not on watchlist,0.0,0.0,trial_collaborator: Anti-CD 19 CAR-T Cell Therapy in Patients with ANCA Vasculitis,https://clinicaltrials.gov/study/NCT06590545,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
36,"Nkarta, Inc.",7.00,3.0,3.0,1.0,1,"NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2024-12-24,"NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",ACTIVE_NOT_RECRUITING,"[""PHASE1""]",2024-12-24,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status ACTIVE_NOT_RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,"trial_candidate: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",https://clinicaltrials.gov/study/NCT05020678,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
37,Adaptive Biotechnologies,7.00,3.0,3.0,1.0,1,Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma,RECRUITING,"[""PHASE2""]",2025-10-22,Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma,RECRUITING,"[""PHASE2""]",2025-10-22,0,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.0,0.0,trial_collaborator: Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma,https://clinicaltrials.gov/study/NCT06252675,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
38,Celgene Corporation,7.00,3.0,3.0,1.0,1,Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE1""]",2025-08-13,Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma,RECRUITING,"[""PHASE1""]",2025-08-13,0,trial title contains known T-cell engager molecule,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,trial_collaborator: Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma,https://clinicaltrials.gov/study/NCT06348108,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
39,Hoffmann-La Roche,7.00,3.0,3.0,1.0,1,"A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).",NOT_YET_RECRUITING,"[""PHASE2""]",2025-09-24,"A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).",NOT_YET_RECRUITING,"[""PHASE2""]",2025-09-24,0,trial title contains known T-cell engager molecule,trial status NOT_YET_RECRUITING and phase in ['PHASE2'],trial,not on watchlist,0.0,0.0,"trial_collaborator: A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).",https://clinicaltrials.gov/study/NCT07191249,"Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development | Clinical Scientist / Early Clinical Development Lead (Phase 1)",[],[]
40,TCRCure Biopharma Ltd.,7.00,3.0,3.0,1.0,1,NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2025-07-16,NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors,RECRUITING,"[""PHASE1""]",2025-07-16,0,trial title contains CAR-T/TCR-T/chimeric antigen receptor,trial status RECRUITING and phase in ['PHASE1'],trial,not on watchlist,0.0,0.0,trial_candidate: NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors,https://clinicaltrials.gov/study/NCT05881525,"Clinical Scientist / Early Clinical Development Lead (Phase 1) | Director/VP, Translational Medicine (Oncology/Immunology) | Head/Director, Clinical Biomarkers / Translational Biomarkers | Head/Director, Immune Monitoring / Flow Cytometry / Cytometry Core | Director, Bioassay / Potency / Analytical Development",[],[]
